Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone

NCT00096213 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.

Conditions Studied

Interventions

  • PROCEDURE conventional surgery

Study Locations (20)

Washington

  • St. Joseph Cancer Center — Bellingham
  • Olympic Hematology and Oncology — Bremerton
  • Skagit Valley Hospital Cancer Care Center — Mount Vernon
  • Fred Hutchinson Cancer Research Center — Seattle
  • Harborview Medical Center — Seattle
  • Minor and James Medical, PLLC — Seattle
  • Group Health Central Hospital — Seattle
  • Swedish Cancer Institute at Swedish Medical Center - First Hill Campus — Seattle
  • Polyclinic First Hill — Seattle
  • University Cancer Center at University of Washington Medical Center — Seattle

Michigan

  • University of Michigan Comprehensive Cancer Center — Ann Arbor
  • William Beaumont Hospital - Royal Oak Campus — Royal Oak

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center — Aurora

Florida

  • University of Florida Shands Cancer Center — Gainesville

New Mexico

  • University of New Mexico Cancer Research and Treatment Center — Albuquerque

Ohio

  • Akron City Hospital — Akron

Oregon

  • Oregon Health & Science University Cancer Institute — Portland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2004-12
Est. Completion 2009-08
Phase Phase 2

Sponsor

SWOG Cancer Research Network

212 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00096213

The ClinicalTrials.gov registry entry for NCT00096213 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention — of which conventional surgery is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00096213 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Washington, Michigan, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00096213 about?

NCT00096213 is a clinical study titled "S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone". RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.

What is the current status of trial NCT00096213?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-12. Estimated completion is 2009-08.

What conditions does trial NCT00096213 study?

This clinical trial studies the following conditions: Sarcoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00096213?

The interventions under investigation include: conventional surgery (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00096213?

This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00096213 being conducted?

This trial has 20 study locations across Arkansas, Colorado, Florida, Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial